Abstract: The present disclosure relates generally to methods of diagnosing Benign Paroxysmal Positional Vertigo (BPPV) in a subject. In particular, the present disclosure relates to methods of genotyping a subject in order to determine the presence or absence of a genetic variation or variations indicative of BPPV. In other embodiments, an inhibitor is administered to a subject, wherein the inhibitor prevents aggregation of proteins in neural cells such as the vestibular ganglia. The disclosure further includes methods of identifying an agent that inhibits the aggregation of proteins in neural cells. Methods of monitoring protein aggregation in neural cells are also provided.